金十数据6月11日讯，自2018年以来，欧洲银行业已斥资逾11亿欧元裁减高级员工，这透露出银行业近 年来经历的重组的程度。对监管机构填写的文件和公司账目的分析，德意志银行、汇丰银行和桑坦德银 行在2018年至2024年期间共向其最高级员工支付了近8.5亿欧元的遣散费。同期，法兴银行、法国巴黎 银行、巴克莱银行和瑞银共向高级员工支付了2.75亿欧元的遣散费。这些支出突显出，近年来，德意志 银行和汇丰银行等几家大型欧洲银行在多大程度上实施了重大重组计划，而其它银行则试图重塑投行业 务，以适应不断变化的市场需求。 （英国金融时报） 欧洲银行业为裁减高级员工花费了11亿欧元 ...

Core Points - The document provides information regarding the total number of voting rights and shares for Sanofi as of May 31, 2025 [1] - Sanofi has a registered share capital of €2,452,461,656 and is registered at the Paris Commercial and Companies Registry [1] Summary by Category Voting Rights - Total number of issued shares is 1,227,755,892 [1] - The number of real voting rights, excluding treasury shares, is 1,351,729,644 [1] - The theoretical number of voting rights, including treasury shares, is 1,361,952,180 [1] Company Information - Sanofi is a French société anonyme with its registered office located at 46, avenue de la Grande Armée, 75017 Paris, France [1] - The company is registered under number 395 030 844 [1]

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend ...

Core Viewpoint - Sanofi is proactively shipping Beyfortus (nirsevimab) to ensure availability ahead of the 2025-2026 RSV season, responding to increasing demand and aiming to support healthcare providers effectively [1][2]. Group 1: Product Availability and Production - Sanofi, in collaboration with AstraZeneca, has tripled production capacity and doubled manufacturing sites since Beyfortus's launch in 2023, with current supply matching last year's total doses distributed [2]. - Advance shipments of Beyfortus are being made to ensure broad availability for the upcoming RSV season, which typically runs from November to March [1]. Group 2: Efficacy and Impact - Beyfortus has shown high, sustained efficacy in protecting infants from RSV, supported by over 40 real-world studies involving 250,000 immunized infants [3]. - The duration of protection for Beyfortus has been extended to six months in the EU, allowing for season-long protection for all infants, including those immunized just before the RSV season [4]. Group 3: Market Context and Health Implications - RSV is highly contagious, infecting two out of three infants in their first year and nearly all children by their second birthday, making it a leading cause of hospitalization among infants worldwide [5]. - Beyfortus is distinguished as the longest-acting monoclonal antibody for RSV prevention, designed to protect all infants regardless of health conditions or timing of birth [6].

6. 野村证券：料降息25个基点，料将在7月和9月进一步降息直至1.50%，料上调今年GDP预测、下调今 年通胀预测。 金十整理：机构前瞻欧洲央行利率决议——宽松周期尾声渐进，欧央行将何时"收手"？ 1. 高盛：料降息25个基点，料保持今年GDP预测不变、下调明年GDP预测，同时料大幅下调通胀预测。 2. 瑞银：料降息25个基点，7月料进行最后一次降息，利率将降至1.75%，2026年底或被迫加息以应对 通胀风险。 3. 美国银行：料降息25个基点，市场已经消化了欧洲央行最近的降息决定，会议不太可能对欧元产生重 大影响。 4. 荷兰国际：料降息25个基点，市场已完全消化欧央行降息25个基点的预期，欧元走势更可能继续由美 元表现主导。 5. 裕信银行：料降息25个基点，6月之后将评估进一步降息的紧迫性，预计9月进行最后一次降息，但并 非板上钉钉。 7. 贝伦贝格：料降息25个基点，之后可能会将利率维持不变，这在很大程度上将取决于欧盟与美国之间 的贸易谈判。 8. 三菱日联：料降息25个基点，前瞻性指引将基本保持不变，进一步降息的门槛或会更高，欧央行或放 缓宽松步伐。 9. 法农信贷：料降息25个基点，或暗示7月 ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse® on-body injector, an automated hands-free injectorData will form the basis of global regulatory submissions across all currently approved lines of treatment P ...

Core Viewpoint - The FDA has granted orphan drug designation to rilzabrutinib for sickle cell disease, highlighting its potential to address unmet medical needs in rare diseases [1][2]. Company Overview - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [7]. Product Information - Rilzabrutinib is a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that aims to restore immune balance through multi-immune modulation [5]. - The drug has received multiple orphan drug designations, including for immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), and IgG4-related disease (IgG4-RD) [2][8]. Disease Context - Sickle cell disease affects over 100,000 people in the US, predominantly impacting African American and Hispanic populations, leading to severe pain and reduced life expectancy [6]. - The disease is characterized by misshapen red blood cells that block blood flow, causing various health complications [6]. Regulatory Status - Rilzabrutinib is currently under regulatory review in the US, EU, and China for its potential use in ITP, with a target action date for FDA decision set for August 29, 2025 [3][8].

桑坦德银行：欧洲央行下周降息已板上钉钉 金十数据5月30日讯，桑坦德银行的G10宏观和固定收益策略研究主管Antonio Villarroya在一份报告中指 出，欧洲央行下周四再降息25个基点、将存款利率降至2.00%已板上钉钉。他表示，问题在于这是否会 是本轮周期的最后一次宽松。Villarroya认为，尽管再次降息的概率低于市场当前定价，但欧洲央行至 少会在与美国关税相关的不确定性消散之前，保留进一步降息的可能性。他指出，未来几个月欧元短期 利率可能较当前水平走高，但这种重新定价可能不会立即发生。 ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefitAERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the studyItepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2Sanofi and Regeneron are assessing the ...

Core Insights - The AERIFY-1 trial demonstrated a statistically significant reduction of 27% in moderate or severe exacerbations in former smokers with COPD compared to placebo at week 52, indicating a clinically meaningful benefit [1][2] - The AERIFY-2 trial did not meet its primary endpoint, although some benefits were observed earlier in the trial [1][3] - Itepekimab was generally well tolerated across both trials, with safety profiles consistent with previous clinical studies [1][5] Trial Details - AERIFY-1 involved 375 patients receiving itepekimab every two weeks, 377 every four weeks, and 375 receiving placebo, while AERIFY-2 included 326 patients every two weeks, 303 every four weeks, and 324 receiving placebo [2][10] - The primary endpoint for both trials was the reduction in the annualized rate of acute moderate or severe COPD exacerbations [12] Efficacy Results - In AERIFY-1, the reduction in exacerbations was 30% at week 24 and 27% at week 52 for the every-two-week group, and 34% at week 24 and 21% at week 52 for the every-four-week group [3] - In AERIFY-2, the reductions were 18% at week 24 and only 2% at week 52 for the every-two-week group, and 21% at week 24 and 12% at week 52 for the every-four-week group [3] Safety Profile - Adverse events (AEs) were comparable between treatment and placebo groups, with AEs reported at 67% and 68% for the every-two-week and every-four-week groups in AERIFY-1, respectively, compared to 68% for placebo [5] - Serious infections occurred in 7% of patients in both itepekimab arms in AERIFY-1, compared to 10% for placebo [5] Future Directions - Regeneron and Sanofi are reviewing the trial data and will discuss next steps with regulatory authorities [1][7] - Itepekimab is also being evaluated in other clinical trials for conditions such as chronic rhinosinusitis and non-cystic fibrosis bronchiectasis [8][15]